Ceftaroline fosamil for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infection (Q38010783)

26 August 2017

title

Ceftaroline fosamil for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infection (English)

1 reference

26 August 2017

0 references

1 reference

ChEBI release 2020-05-28

1 reference

4

Michael J Rybak

1 reference

26 August 2017

Anthony M Casapao

1

1 reference

26 August 2017

Molly E Steed

series ordinal

2

1 reference

26 August 2017

Donald P Levine

series ordinal

3

1 reference

26 August 2017

language of work or name

English

0 references

publication date

1 June 2012

1 reference

Expert Opinion on Pharmacotherapy

26 August 2017

published in

1 reference

26 August 2017

volume

13

1 reference

26 August 2017

issue

8

1 reference

26 August 2017

page(s)

1177-1186

1 reference

Comparison of Incidence of Bloodstream Infection with Methicillin‐ResistantStaphylococcusaureusbetween England and United States, 2006–2007

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685718

Methicillin-resistant Staphylococcus aureus disease in three communities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685718

Epidemiology and outcomes of complicated skin and soft tissue infections in hospitalized patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685718

Invasive methicillin-resistant Staphylococcus aureus infections in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685718

Vancomycin: a 50-year reassessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685718

Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685718

Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685718

Ceftaroline: a new cephalosporin with activity against resistant gram-positive pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685718

Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685718

Stability and stabilization studies of TAK-599 (Ceftaroline Fosamil), a novel N-phosphono type prodrug of anti-methicillin resistant Staphylococcus aureus cephalosporin T-91825.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685718

TAK-599, a novel N-Phosphono type prodrug of anti-MRSA cephalosporin T-91825: synthesis, physicochemical and pharmacological properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685718

Co-opting the cell wall in fighting methicillin-resistant Staphylococcus aureus: potent inhibition of PBP 2a by two anti-MRSA beta-lactam antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685718

Binding of ceftaroline to penicillin-binding proteins of Staphylococcus aureus and Streptococcus pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685718

In vitro activity of ceftaroline against gram-positive and gram-negative pathogens isolated from patients in Canadian hospitals in 2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685718

Activity of ceftaroline and epidemiologic trends in Staphylococcus aureus isolates collected from 43 medical centers in the United States in 2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685718

Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685718

Antimicrobial activities of Ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685718

Evaluation of ceftaroline activity versus daptomycin (DAP) against DAP-nonsusceptible methicillin-resistant Staphylococcus aureus strains in an in vitro pharmacokinetic/pharmacodynamic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685718

In vitro activity of ceftaroline against Streptococcus pneumoniae isolates exhibiting resistance to penicillin, amoxicillin, and cefotaxime.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685718

In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685718

In vitro antimicrobial activity of T-91825, a novel anti-MRSA cephalosporin, and in vivo anti-MRSA activity of its prodrug, TAK-599.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685718

Activity of the new cephalosporin ceftaroline against bacteraemia isolates from patients with community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685718

Ceftaroline versus ceftriaxone in a highly penicillin-resistant pneumococcal pneumonia rabbit model using simulated human dosing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685718

Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685718

In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685718

In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685718

In vitro activity of ceftaroline against a broad spectrum of recent clinical anaerobic isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685718

Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685718

Efficacy of human simulated exposures of ceftaroline administered at 600 milligrams every 12 hours against phenotypically diverse Staphylococcus aureus isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685718

In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685718

Evaluation of PPI-0903M (T91825), a novel cephalosporin: bactericidal activity, effects of modifying in vitro testing parameters and optimization of disc diffusion tests.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685718

Multistep resistance development studies of ceftaroline in gram-positive and -negative bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685718

A prediction rule to identify low-risk patients with community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685718

Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685718

Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685718

Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685718

In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.685718

10.1517/14656566.2012.685718

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference